Dr. Limdi is a clinical pharmacist and epidemiologist with significant expertise in pharmacogenomics and pharmacoepidemiology, from research and discovery to its application and implementation in clinical practice. Her research portfolio encompasses studies with both observational and a clinical trial designs and is focused on understanding the multiple factors that influence drug efficacy and safety, specifically anticoagulant and antiplatelet response. An established investigator in the field of pharmacogenomics, she has made significant contributions towards understanding of genetic basis of warfarin response. Her work has included discovering novel polymorphisms in CYP2C9, statistical analytic approaches that has ranged from candidate gene, haplotype based approach to genome-wide association and exome approaches, and a research portfolio that includes both prospective cohort and randomized clinical trials.
Through her work, Dr. Limdi has collaborated extensively with pharmacogenomics researchers including with the International Warfarin Pharmacogenomics Consortium (IWPC), the Clinical Pharmacogenetics Implementation Committee (CPIC), and the Implementation of Genomics In pracTicE (IGNITE). As the Associate Director of Pharmacogenomics n the Hugh Kaul Personalized Medicine Institute, Dr. Limdi oversees discovery and clinical implementation of pharmacogenomics across the health UAB system. Through this initiative, her team has identified and overcome barriers, incorporated genotype-guided therapy and assessed clinically relevant outcomes to conduct economic analysis and inform health policy and reimbursement strategies for pharmacogenomics.
Harnessing the racial diversity of the population served at UAB, Dr. Limdi research and practice interests center around the evaluation of racial differences in the genetic underpinnings for drug response. 1. Discovery of genetic variants and environmental factors influencing drug response 2. Integrating clinical, genetic, socio-demographic and behavioral data to predict drug response 3. Translating pharmacogenomic discoveries to health disparity populations 4. Development of statistical genetic analysis approaches and methodologies 5. Advancing Pharmacogenomics through collaborations with national and international consortia.
In addition to research and implementation, Dr. Limdi is committed to developing talent through mentorship: She brings a comprehensive and diverse set of skills, and expertise in pharmacy practice, pharmacology, pharmacogenomics, clinical research methods, epidemiology and biostatistics to didactic teaching and training residents, post-doctoral trainees and junior faculty.